李艳 女 汉族 博导 昆明植物研究所
电子邮件:liyanb@mail.kib.ac.cn
联系电话:0871-65223088
传真: 0871-65223088
通信地址:昆明市蓝黑路132号昆明植物研究所
邮政编码:650201

研究领域

天然产物是抗肿瘤药物的主要来源,60%以上的临床使用药物与天然产物相关,比如紫杉醇和长春花碱类药物等。课题组依托植物化学及西部植物资源持续利用国家重点实验室的天然产物研究优势,首先利用各种现代生物学技术构建较为系统的分子靶点信号通路以及细胞水平的抗肿瘤药物筛选平台,对天然小分子化合物进行抗肿瘤活性筛选,并应用生物化学,化学生物学以及药理学的手段,围绕肿瘤增殖和凋亡密切相关的分子信号通路进行深入的药物作用机理研究以及新的药物作用靶点探索,为研发抗肿瘤天然创新药物奠定基础。

真诚欢迎有志于从事创新抗肿瘤药物研究的学生报考,以及具有肿瘤及其药物的分子生物学相关机理研究经历或者从事肿瘤药物筛选的研究人员或者客座研究人员来课题组开展工作。

招生信息

招生专业:生物化学及分子生物学,药理学
招生方向:天然药物筛选及作用机理研究
考试科目:细胞生物学,生物化学或者分子药理学

教育和工作经历

   
学历
1991-1995,山东大学,生物化学学士
1995-1998,山东大学,细胞生物学硕士
1998-2001,山东大学,德国癌症研究中心合作培养,发育生物学博士
2002-2003,德国国家癌症研究中心(DKFZ),博士后
2003-2007,美国辛辛那提儿童医院医学中心(CCHMC),博士后
2007 -至今,中科院昆明植物研究所,植物化学与西部植物资源持续利用国家重点实验室,肿瘤药物筛选及研究课题组长,研究员,博导

专利与奖励

2009年,入选中科院“****”
2009年,入选云南省“高端科技引进人才” 
2011年,入选云南省“首批引进高层次人才”
申请以及参与申请并获得授权专利11项

代表论文

       1. Zhou HY#, Yu CL#, Kong LM#, Xu XL, Yan JM,  Li YC, An T, Gong L, Gong YX, Zhu HF, Zhang HB*Yang XD*, Li Y*. B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells. Oncogene, 2019, DOI: 10.1038/s41388-018-0674-5        

        2. Tang JW#, Kong LM#, Zu WY, Hu K, Su XZ, Li XN, Yan BC, Wang WG, Sun HD, Li Y*, Puno PT*. Isopenicins A–C: Two Types of Novel Antitumor Meroterpenoids from the Plant Endophytic Fungus Penicillium sp. sh18. Organic Letters, 2019, DOI: 10.1021/acs.orglett.8b04020

        3. Gao ZH#, Chen KQ#, Zhang Y, Kong LM, Li Y*, Ye S*. Enantioselective N.Heterocyclic Carbene-Catalyzed Synthesis of Spirocyclic Oxindole-benzofuroazepinones. The Journal of Organic Chemistry, 2018, 83, 15225-15235

        4. An T, Gong YX, Li X, Kong LM, Ma PC, Gong L, Zhu HF, Yu CL, Liu JM, Zhou HY, Mao BY, Li Y*. USP7 inhibitor P5091 inhibits Wnt signaling and coloreal tumor growth. Biochemical Pharmacology, 2017.02.11. 131(1):29-39

  5. Yu CL, Gong YX, Zhou HY, Wang M, Kong LM, Liu JM, An T, Zhu HF, Li Y*. Star-PAP, a poly(A) polymerase, functions as a tumor suppressor in an orthpic humanbreast cancer model. Cell Death & Disease, 2017, 8 (2): e2582.

  6. Shao LD#, Su J#, Ye BX#, Liu JX#, Zuo ZL, Li Y, Wang YY*, Xia CF*, Zhao QS*. Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C-Terminal Inhibitors. Journal of Medicinal Chemistry, 2017, 60 (21): 9053–9066 60(21).

  7. Zhou HY#, Shang CW#, Wang M, Shen T, Kong LM, Yu CL, Ye ZN, Luo Y, Liu L, Li Y*, Huang SL*. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK. Biochemical Pharmacology, 2016, 16:39-50

  8. Wang M, Zhou AK, An T, Kong LM, Yu CL, Liu JM, Xia CF*, Zhou HY*, Li Y*. N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells. Journal of Experimental & Clinical Cancer Research, 2016, 35:41

  9. Li XY , Bai B, Liu L, Ma PC, Kong LM, Yan JM, Zhang J, Ye ZN, Zhou HY, Mao BY , Zhu HJ* and Li Y*. Novel β-Carbolines Against Colorectal Cancer Cell Growth Via  Inhibition of Wnt/β-catenin signaling. Cell Death & Discovery 2015,1, 15033

  10. Kong LM, Mao BY, Zhu HJ* and Li Y*. Novel β-carbolines inhibit Wnt/β-catenin signaling. Cell Death & Disease, 2015, 6, e1983

  11. Ye ZN, Yu MY, Kong LM, Wang WH, Yang YF, Liu JQ, Qiu MH*, Li Y*. Biflavone Ginkgetin, a Novel Wnt Inhibitor, Suppresses the Growth of Medulloblma. Natural Products and Bioprospecting, 2015, 5(2): 91–97

  12. Ma PC, Yang XC, Kong QH, Li CC, Yang SJ, Li Y, Mao B*. The Ubiquitin Ligase RNF220 Enhances Canonical Wnt Signaling through USP7-Mediated Deubiquitination of β-Catenin. Mol Cell Biol, 2014, 34(23):4355-66

  13. Zhou HY, Shen T, Shang C, Lou Y, Liu L, Yan J, Li Y*, Huang S*. Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK  signaling pathway. Oncotarget, 2014, 5(20):10140-50.

  14. Kong LM#, DengX#, Zuo ZL, Sun HD, Zhao QS*, Li Y*. Identification and validation of p50 as the cellular target of eriocalyxin B. Oncotarget, 2014, 5(22):11354-64

  15. Liu WP, Su J, Jiang J, Li XY, Ye QS, Zhou HY, Chen JL, Li Y*. Two mixed-NH3/amine platinum (II) anticancer complexes featuring a dichloroacetate moiety in the leaving group. Scientific Reports, 2013, 3 : 2464.

  16. Li XY, Pu JX, Jiang SY, Su J, Kong LM, Mao BY, Sun HD*, Li Y*. Henryin, an ent-kaurane Diterpenoid, Inhibits Wnt Signaling through Interference with β-Catenin/TCF4 Interaction in Colorectal Cancer Cells. PLoS One, 2013, 8(7):e68525.

  17. Zhao Y#, Su J#, Goto M, Morris-Natschke SL, Li Y, Zhao QS*, Yao ZJ*, Lee KH*, Dual-functional abeo-taxane derivatives destabilizing microtubule equilibrium and inhibiting NF-κB activation. J Med Chem, 2013, 56(11):4749-57.

  18. Liu LX, Wang XQ, Yan JM, Li Y*, Sun CJ, Chen W, Zhou B, Zhang HB, Yang XD*, Synthesis and antitumor activities of novel dibenzo[b,d]furan-imidazole hybrid compounds. Eur J Med Chem, 2013, 66:423-37.

  19. Li XY, Wang YY, Yuan CM, Hao XJ*, Li Y*. A reporter gene system for screening inhibitors of Wnt signaling pathway. Natural Products and Bioprospecting, 2013, 3, 24-28.

  20. Li Y#, Rankin SA#, Sinner D, Kenny AP, Krieg PA, Zorn AM*, Sfrp5 coordinates foregut specification and morphogenesis by antagonizing both canonical and noncanonical Wnt11 signaling. Genes Dev, 2008, 22(21), 3050-63.

  21. Pollet N*, Muncke N, Verbeek B, Li Y, Fenger U, Delius H, Niehrs C*, An atlas of differential gene expression during early Xenopus embryogenesis. Mech Dev, 2005,122(3), 365-439.

  22. Li Y, Fenger U, Niehrs C, Pollet N*, an Cyclic expression of esr9 gene in Xenopus presomitic mesoderm. Differentiation, 2003,71(1), 83-9.

  23. Mao B#, Wu W#, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C*, LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature, 2001, 411(6835), 321-5


科研项目

1.“云南省联合基金重点项目U1402227”国家基金委,2015-2019,新型mTOR信号通路抑制剂及其抗肿瘤活性和作用机制研究
2.“973”项目课题2005CB522305,中国科技部,2009-2013,天然产物抗肿瘤活性筛选及作用机理研究。
3.“云南省高端科技引进人才”,云南省科技厅,2009-2013,天然抗肿瘤药物筛选及作用机理研究。
4.“****”项目,中国科学院,2010-2014,天然抗肿瘤药物筛选及作用机理研究。
5.“国家自然科学基金”面上项目,2011-2015,靶向wnt信号通路的天然产物(思茅山橙素甲)的抗肿瘤活性及作用机制研究。